This study examined the current state of the representative support projects for each government that have been promoted to foster local industries. We have identified the changes and focus areas of the supporting industries in the biotechnology and medical industry sectors selected by each region. As a result, we found that most of the support for the bio and medical industry is concentrated in the industrial biotechnology field. We found that continued investment by governments and local governments had an impact on the growth of the biomedical industry In addition, an analysis of the results for 15 years (2002~ 2006) on sales and net profit (net loss) showed that productivity and growth were affected.

최근 출산율의 감소와 고령화 추세에 따른 인구구조의 급격한 변화로 인하여 보건의료산업의 중요성이 높아지고 있다. 이미 많은 선진국들은 IT관련 산업에서 벗어나 전략산업으로 보건의료(HT: Health technology) 산업을 집중육성하고 있다. 한국도 경제성장을 통하여 소득수준이 향상되면서, 국민들은 건강에 대한 관심이 높아지고 이에따라 보건의료에 대한 국민적 수요가 증대됨으로 인하여 정부차원의 연구개발 투자의 확대가 필요하다.이에 본 연구는 산업연관분석을 이용하여 보건의료산업에 대한 국가 연구개발(R&D: Research and Development) 투자가 국민경제에 미치는 효과를 수치화해보고자 한다. 위 분석은 국가 R&D 투자가 이루어지는 보건의료산업을 내생부분이 아닌 외생화시켜 타 산업분야에 대한 순수한 파급 효과를 분석하였다. 분석 결과, 보건의료산업의 생산 및 부가가치유발 효과는 공통적으로 부동산 및 사업서비스와 금융 및 보험부문이 높게 나왔다. 이러한 부문은 보건의료산업과 관련이 있는 세부분류를 포함하고 있음을 의미한다. 또한 보건의료산업의 취업유발효과는 도소매부문이 가장 높은 수치를 나타냈으며, 그 뒤를 부동산 및 사업서비스, 농림수산품 부문 순으로 나타났다. 보건의료산업의 전⋅후방 연쇄효과는 평균인 1보다 낮은 수준을 보이고 있는데 이는 보건의료산업이 최종수요적 원시산업의 형태를 가지고 있다는 것을 의미한다. 또한 실제 2009년 보건의료산업 관련 국가 R&D투자금액을 대입하여 보건의료관련 정부연구개발비가 경제에 미치는 생산 및 부가가치 금액을 도출해본 결과 전체산업에 생산유발은 약 4,932억원, 부가가치유발은 약 2,163억원의 경제적 파급효과를 미치는 것으로 분석되었다.

The existing evaluation systems based on financial performance summarize the information about past results and focus on short-term performance, and so they have the limits to explain the future value of firms and to make a long-term strategic performance. By this reason, as a way to increase the future value, the development of the integrated performance evaluation system with which we may manages financial performance and knowledge assets together has been required recently. This study puts together various researches for the evaluation of knowledge assets, and analyzes the existing studies for the domestic medical devices industry and the tendency of introduction for business practice. Under this analysis, this study develops the knowledge asset evaluation indexes for medical devices industry by using the Balanced Score Card (BSC) of Kaplan & Norton(1992), and then presents the evaluation model by applying the Analytic Hierarchy Process (AHP) of Saaty(1980) to get the weight for each index. With the final evaluation model, we can calculate the evaluation score combined with both the quantitative indexes and the qualitative indexes at once.

The health industry is highly value-added, compared to other industries. The reason is that increase of income growth and the expanded human life expectancy bring about positively needs of products at health industry. This is related with increase in expenses of health care and R&D investment of health industry. After 1995, the share of GDP at drug & biomedical industry is increased. Especially, the share of GDP at biomedical is 0.12% in 1995 1st quarter, but 0.17% in 2002 3rd quarter, 0.24% in 2008. Biomedical's contribution about GDP growth is to jump into 6.01% in 2008. The share of GDP at drug will continuously expand, compared to other manufacture industries. Also, drug's contribution about GDP growth will increase, compared with before. Conclusionally, total shares of GDP at drug St biomedical industry are to increase, compared with before. Also, this health industry's contribution is to expand as value-added industry and increase of sales.

Purpose - With the worldwide aging problem and the development of globalization, customers prefer to seek affordable medical services with the higher quality overseas. This new trend has urged some destination countries to improve their services for the more competitive advantages over other countries. Literature research indicate that medical quality and cost may be the key factors influencing global patients’ decisions. In the international environment, however, medical tourism destinations are selected due to cultural similarity between the hosting country and the customers’ own country. The more similarity perceived between the two countries leads foreign patients to choose the considering country as the destination for medical tourism. However, little research has been conducted on this topic. Thus, we empirically investigate how cultural similarity influences Chinese medical customers’ choice of the destinations. We also consider the factors related to medical competency and travel attribute which might affect customers’ decisions along with some moderating roles of disease types. Research design, data, and methodology – We proposed a research model in order to confirm the relations among different variables of cultural similarity, medical competency, travel attractiveness, disease types, and destination choice. The questionnaire survey is processed in the more economically developed regions of China such as Beijing, Shanghai, and Jiangsu. Conditional logit regression is applied to analyze the data of 881. Results - Results indicate that cultural similarity is the important predictor of Chinese customers’ decision to select a medical country. However, the effects of cultural similarity vary according to the disease types. We also find that medical competency and travel attractiveness influence their decisions with the moderating role of disease types. Conclusions – Cultural similarity is the important factor that influences Chinese potential medical tourists’ decisions to select a destination. Marketing managers should consider the effects of cultural similarity when developing strategies for attracting Chinese medical tourists. Since medical competency and travel attractiveness are still the critical key elements for them to evaluate the destination countries, it is necessary to continuously improve medical service quality and facilities. The results also recommend that medical managers should sharpen their marketing strategies by segmenting Chinese potential customers in terms of disease types.